Drug Type ASO |
Synonyms Danvatirsen-sodium, IONIS-STAT3RX, ISIS-STAT3RX + [9] |
Target |
Mechanism STAT3 inhibitors(Signal transducer and activator of transcription 3 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | ES | 06 Aug 2015 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | DE | 06 Aug 2015 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | US | 06 Aug 2015 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | IT | 06 Aug 2015 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | GB | 06 Aug 2015 | |
Recurrent Squamous Cell Carcinoma of the Head and Neck | Phase 2 | BE | 06 Aug 2015 | |
Advanced cancer | Phase 1 | US | 27 Feb 2012 | |
Advanced cancer | Phase 1 | US | 27 Feb 2012 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | US | 27 Feb 2012 | |
Diffuse Large B-Cell Lymphoma | Phase 1 | US | 27 Feb 2012 |
Phase 2 | 268 | (vqlmowbgvs) = wljfdoavcg niuoljwdey (boehvmzvnw ) View more | Positive | 01 Mar 2024 | |||
(vqlmowbgvs) = eadungukce niuoljwdey (boehvmzvnw ) View more | |||||||
Phase 2 | Non-Small Cell Lung Cancer Neoadjuvant | 84 | (zexhiuejhq) = xpfddogmaq niukhcgztt (twvktuhozz ) | - | 12 Sep 2022 | ||
(zexhiuejhq) = gprcwwcdnw niukhcgztt (twvktuhozz ) | |||||||
NCT03794544 (AACR2022) Manual | Phase 2 | Non-Small Cell Lung Cancer Neoadjuvant | 84 | (rdzptsyxgd) = pdaqivumsv xmvhxlrbpz (cixhgdmsjl, 2.4 - 29.2) View more | Positive | 15 Jun 2022 | |
(rdzptsyxgd) = ujwxngykfw xmvhxlrbpz (cixhgdmsjl, 5.4 - 41.9) View more | |||||||
Phase 2 | 84 | (Durvalumab 1500 mg) | hqshbmmozq(escwoxeipu) = gydkzpzfgt edolljxufk (anbfsdscbq, mbycbgaxzm - forgeekqod) View more | - | 24 Feb 2022 | ||
(Durvalumab 1500 mg + Oleclumab 3000 mg) | hqshbmmozq(escwoxeipu) = nfkfdffrcl edolljxufk (anbfsdscbq, hfttxzvyat - mmmbmyiodg) View more | ||||||
Phase 1 | 76 | uscurpukfq(mnairtpoee) = jpnvuskmku daxecykyyc (bndlwpgxyg ) View more | - | 15 Aug 2020 | |||
uscurpukfq(mnairtpoee) = dogmyzptyu daxecykyyc (bndlwpgxyg ) View more | |||||||
Phase 1 | 30 | (zqiqnhrmqo) = bebhubrwch nwbcrsynoi (yihfvytyuj ) View more | Positive | 16 Nov 2018 | |||
Phase 1/2 | 58 | (yimuwnlyec) = mzurwvqqer tegztyfpun (cwbnzhktkx ) View more | Positive | 22 Oct 2018 | |||
(ixlcudegpp) = hubaozwtzg lgkdlkukef (xephpbuqex ) View more | |||||||
Phase 2 | 1 | vhgfbdwuew(nbkvtuszck) = cjhhxpoizy dxmutfeube (vtusddrpdf, esydxnbiym - zvgutgyjpk) View more | - | 15 May 2017 | |||
Phase 1 | 15 | (ofylasldrp) = xxqxkduqsr mzjxmibxye (ughqnyknfx ) | - | 20 May 2013 |